Gene therapy pioneer James Wilson sounds an alarm on high-dose AAV studies following toxic reactions in monkeys – Endpoints News
Endpoints News |
Gene therapy pioneer James Wilson sounds an alarm on high-dose AAV studies following toxic reactions in monkeys
Endpoints News Penn professor James Wilson is one of the preeminent scientists working today in gene therapy. He’s also the key figure in a fatal gene therapy trial back in the late ’90s that left the field in limbo for years, until a new generation of biotechs … Gene Therapy May Not Be a Viable Option for Many PatientsGenetic Engineering & Biotechnology News |
Medscape |
Clinical Cancer Advance of the Year Is CAR T Cells
Medscape This product “can eradicate relapsed ALL in children. This represents one of the most remarkable advances in the treatment of childhood cancer in the last decade and could dramatically change treatment paradigms for this disease,” the report authors … ASCO Names CAR T-Cell Therapy as Cancer Advance of the YearOncLive CAR T-cell therapy named ASCO’s ‘Advance of the Year’Healio |
|
Blood Test to Determine Which Patients Will Respond to Immunotherapy
Technology Networks A test that measures the levels of two types of immune cell in the blood could identify which cancer patients are most likely to respond to immunotherapy. The test gives a measure of a patient’s immune system health by comparing the number of … |
Technology Networks |
Blood Test to Determine Which Patients Will Respond to Immunotherapy
Technology Networks A test that measures the levels of two types of immune cell in the blood could identify which cancer patients are most likely to respond to immunotherapy. The test gives a measure of a patient’s immune system health by comparing the number of … |
OncLive |
ASCO Names CAR T-Cell Therapy as Cancer Advance of the Year
OncLive The FDA approved a pair of CAR T-cell therapies in 2017: tisagenlecleucel (Kymriah) for the treatment of children and young adults aged up to 25 with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) and axicabtagene ciloleucel … CAR T-cell therapy named ASCO’s ‘Advance of the Year’Healio |
The Institute of Cancer Research |
Blood test could indicate which patients will respond to …
The Institute of Cancer Research A test that measures the levels of two types of immune cell in the blood could identify which cancer patients are most likely to respond to immunotherapy. The test gives a measure of a patient’s immune system health by comparing the number of … |
Nature.com |
The messy biological basis of culture
Nature.com Still, The Strange Order of Things addresses several important questions. One of the more compelling consequences of Damasio’s organic linkage of mental processes to the properties of biological hardware is that tinkering — such as the use of … |